Development of an anti-inflammatory diet for first-episode psychosis (FEP): a feasibility study protocol

被引:0
作者
Kennedy, Leda [1 ]
Holt, Tiffany [2 ]
Hunter, Anna [2 ]
Golshan, Shahrokh [2 ]
Cadenhead, Kristin [1 ]
Mirzakhanian, Heline [1 ]
机构
[1] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92093 USA
[2] Univ Calif San Diego, Ctr Integrat Med, San Diego, CA USA
来源
FRONTIERS IN NUTRITION | 2024年 / 11卷
关键词
first-episode psychosis; inflammation; dietary intervention; nutrition; protocol; 1ST EPISODE PSYCHOSIS; MENTAL-ILLNESS; KETOGENIC DIET; FOLLOW-UP; SCHIZOPHRENIA; SYMPTOMS; INTERVENTIONS; INFLAMMATION; MODULATE; OUTCOMES;
D O I
10.3389/fnut.2024.1397544
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Evidence suggests inflammation plays a role in the pathophysiology of psychosis even in early illness, indicating a potential avenue for anti-inflammatory interventions that simultaneously address high rates of metabolic disease in this population. The aim of this study is to design a novel anti-inflammatory diet intervention (DI) that is feasible to implement in a first-episode psychosis (FEP) population. Methods: Eligible FEP Participants are aged 15-30. The DI is currently being refined through a multi-phase process that includes the recruitment of focus groups that provide insight into feasibility of measures and nutritional education, as well as the implementation of the DI. The phases in the study are the Development Phase, Formative Phase, and the Feasibility Phase. Results: The Development phase has resulted in the creation of a flexible DI for FEP based on existing research on nutritional health and informed by providers. This study has just completed the Formative phase, recruiting eligible participants to join focus groups that gleaned information about dietary habits, preferences, and food environments to further refine the DI. Conclusion: Findings from earlier phases have advised the current Feasibility Phase in which this novel DI is being administered to a small cohort of FEP participants (N = 12) to determine acceptability of the DI from a lived experience perspective. Naturalistic changes in inflammatory biomarkers, metabolic health, and symptoms will also be measured.
引用
收藏
页数:13
相关论文
共 89 条
  • [11] The Early Psychosis Intervention Center (EPICENTER): development and six-month outcomes of an American first-episode psychosis clinical service
    Breitborde, Nicholas J. K.
    Bell, Emily K.
    Dawley, David
    Woolverton, Cindy
    Ceaser, Alan
    Waters, Allison C.
    Dawson, Spencer C.
    Bismark, Andrew W.
    Polsinelli, Angelina J.
    Bartolomeo, Lisa
    Simmons, Jessica
    Bernstein, Beth
    Harrison-Monroe, Patricia
    [J]. BMC PSYCHIATRY, 2015, 15
  • [12] Review of the operational definition for first-episode psychosis
    Breitborde, Nicholas J. K.
    Srihari, Vinod H.
    Woods, Scott W.
    [J]. EARLY INTERVENTION IN PSYCHIATRY, 2009, 3 (04) : 259 - 265
  • [13] Design of an anti-inflammatory diet (ITIS diet) for patients with rheumatoid arthritis
    Bustamante, Marta F.
    Agustin-Perez, Meritxall
    Cedola, Francesca
    Coras, Roxana
    Narasimhan, Rekha
    Golshan, Shahrokh
    Guma, Monica
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 17
  • [14] Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium
    Cadenhead, Kristin S.
    Minichino, Amedeo
    Kelsven, Skylar
    Addington, Jean
    Bearden, Carrie
    Cannon, Tyrone D.
    Cornblatt, Barbara A.
    Mathalon, Dan
    McGlashan, Thomas H.
    Perkins, Diana O.
    Seidman, Larry J.
    Tsuang, Ming
    Walker, Elaine F.
    Woods, Scott W.
    Yao, Jeff
    [J]. SCHIZOPHRENIA RESEARCH, 2019, 204 : 96 - 103
  • [15] An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis
    Cakici, N.
    van Beveren, N. J. M.
    Judge-Hundal, G.
    Koola, M. M.
    Sommer, I. E. C.
    [J]. PSYCHOLOGICAL MEDICINE, 2019, 49 (14) : 2307 - 2319
  • [16] Cha Hee Yun, 2020, Clin Nutr Res, V9, P241, DOI 10.7762/cnr.2020.9.4.241
  • [17] SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
    Chan, An-Wen
    Tetzlaff, Jennifer M.
    Altman, Douglas G.
    Laupacis, Andreas
    Gotzsche, Peter C.
    Krleza-Jeric, Karmela
    Hrobjartsson, Asbjorn
    Mann, Howard
    Dickersin, Kay
    Berlin, Jesse A.
    Dore, Caroline J.
    Parulekar, Wendy R.
    Summerskill, William S. M.
    Groves, Trish
    Schulz, Kenneth F.
    Sox, Harold C.
    Rockhold, Frank W.
    Rennie, Drummond
    Moher, David
    [J]. ANNALS OF INTERNAL MEDICINE, 2013, 158 (03) : 200 - +
  • [18] The Inflamed Brain in Schizophrenia: The Convergence of Genetic and Environmental Risk Factors That Lead to Uncontrolled Neuroinflammation
    Comer, Ashley L.
    Carrier, Micael
    Tremblay, Marie-Eve
    Cruz-Martin, Alberto
    [J]. FRONTIERS IN CELLULAR NEUROSCIENCE, 2020, 14
  • [19] Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders Baseline Results From the RAISE-ETP Study
    Correll, Christoph U.
    Robinson, Delbert G.
    Schooler, Nina R.
    Brunette, Mary F.
    Mueser, Kim T.
    Rosenheck, Robert A.
    Marcy, Patricia
    Addington, Jean
    Estroff, Sue E.
    Robinson, James
    Penn, David L.
    Azrin, Susan
    Goldstein, Amy
    Severe, Joanne
    Heinssen, Robert
    Kane, John M.
    [J]. JAMA PSYCHIATRY, 2014, 71 (12) : 1350 - 1363
  • [20] Inflammatory biomarkers in psychosis and clinical high risk populations
    Delaney, Shannon
    Fallon, Brian
    Alaedini, Armin
    Yolken, Robert
    Indart, Alyssa
    Feng, Tianshu
    Wang, Yuanjia
    Javitt, Daniel
    [J]. SCHIZOPHRENIA RESEARCH, 2019, 206 : 440 - 443